Shares of ResMed Inc. RMD rose 1.12% to $239.78 Friday, on what proved to be an all-around positive trading session for the stock market, with the S&P 500 Index SPX rising 1.00% to 5,996.66 and the ...

Shares of ResMed Inc. RMD rallied 1.61% to $237.13 Thursday, on what proved to be an all-around poor trading session for the ...

Goldman Sachs initiated coverage on ResMed Inc (NYSE:RMD) with a "Buy" rating and a price target of A$48.9, driven by strong growth prospects in its continuous airway pressure (CPAP) therapy segment.

Sleep apnea or other forms of the sleep disorder require an effective CPAP machine to enhance your health and sleep patterns.

Goldman Sachs initiated coverage of ResMed (RMD) with a Buy rating and A$48.90 price target The firm says its Buy thesis is based on “robust” ...